Anti-EGFR liposomal drug delivery system loaded with AGY2 potentiates the anti-cancer effect of AGY2 against EGFR expressed pancreatic cancer
offers a promising therapeutic platform capable of overcoming drug delivery barriers and improving outcomes in PDAC therapy.
Authors
- Edward Agyare (ORCID: https://orcid.org/0000-0002-6905-5136)
- Esther Frimpong (ORCID: https://orcid.org/0000-0001-6908-823X)
- Raviteja Bulusu (ORCID: https://orcid.org/0000-0003-4613-4621)
- Xue Zhu
- Sunil Krishnan
- Bo Han
- Joy Okoro
- Saunjoo Yoon
Institutions
- University of Southern California (US)
- University of Florida (US)
- The University of Texas Health Science Center (US)
- Florida Agricultural and Mechanical University (US)
Publication Details
- Journal
- International Journal of Pharmaceutics X
- Published
- 2026-04-15
- DOI
- https://doi.org/10.1016/j.ijpx.2026.100544
- Primary Topic
- Clusterin in disease pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Cancer Institute